If you suffer from chronic back pain, you're not alone. Lower back pain is the second most common cause of disability in the United States and employees miss a combined 149 million days of work every year because of it. Clearly, treatment options for lower back pain fall short. However, that could change because Nektar Therapeutics (NASDAQ: NKTR)has just filed for approval from the Food and Drug Administration of NKTR-181, a novel painkiller that could work better than opioids.
Is Nektar Therapeutics a buy?Can Nektar Therapeutics Disrupt This $20 Billion Market?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться